BQ323636.1, a novel splice variant to NCOR2, as a predictor for tamoxifen resistant breast cancer by Gong, Chun et al.
 1 
 
BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen 
Resistant Breast Cancer 
Chun Gong
1,2
, Ellen PS Man
1
, Ho Tsoi
1
, Terence KW Lee
3
, Lee Paul
1
, Sai-Ting Mak
1
, 
Lai-Shan Wong 
4
, Mei-Yee Luk 
4
, Emad A. Rakha
5
, Andrew R Green
5
, Ian O Ellis
5
, 
Eric WF Lam
2
, Kwok-Leung Cheung
5
, Ui-Soon Khoo
1# 
 
1
Department of Pathology, Li Ka Shing Faculty of Medicine, the University of Hong 
Kong, Hong Kong; 
2
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital 
Campus, London, UK; 
3
Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic 
University, Hong Kong; 
4
Department of Clinical Oncology, Queen Mary Hospital, Hong Kong; 
5
Academic Pathology, Division of Cancer and Stem Cells, School of Medicine, 
University of Nottingham, Nottingham, UK. 
 
#
Corresponding Author: Ui-Soon Khoo, Rm 324, 3/F, University Pathology Building, 
Queen Mary Hospital, Pokfulam Road, Hong Kong SAR, China.  
Phone: 852-22554410; Fax: 852-2218-5205; Email: uskhoo@pathology.hku.hk 
 
Keywords: NCOR2/SMRT; BQ323636.1; Tamoxifen-resistance; breast cancer 
Running title: BQ323636.1 predicts tamoxifen response in breast cancer  
 
 2 
 
Authors contribution: Chun Gong: development of methodology, acquisition, analysis 
and interpretation of data, writting, review and revision of the manuscript; Ellen PS 
Man: development of methodology, acquistion and analysis of data, review and 
revision of the manuscript; Lee Paul, Sai-Ting Mak: acquisition of data; Lai-Shan 
Wong, review and revision of the manuscript; Mei-Yee Luk reviewed clinical 
information. Ho Tsoi: acquisition and analysis of data, review and revision of the 
manuscript; Emad A. Rakha, Andrew R Green, Ian O Ellis, Kwok-Leung Cheung: 
provided clinical samples, review and revision of the manuscript; Eric WF Lam, 
Terence KW Lee, and Ui-Soon Khoo: conception and design and study supervision, 
review and revision of the manuscript.  
 
Financial support: This study was supported by grants from the Innovative 
Technology Fund, HKSAR (ITF Ref.  ITS/015/13), and the Committee on Research 
and Conference Grants from the University of Hong Kong Project no.  201309176148.  
 
Conflicts of interest: Authors of this article declare there is no conflict of interest.  
  
 3 
 
Translational Relevance: 
More than two-thirds of all breast cancers are ER-positive. However, almost half of 
these treated with tamoxifen eventually develop resistance. By the time drug resistance 
is established, the cancer has already progressed and sometimes metastasized. The 
development of reliable biomarker, such as BQ, which could be assessed by 
immunohistochemistry on formalin fixed paraffin embedded tissue sections of newly 
diagnosed primary breast cancer would enable appropriate alternative therapy to be 
given at an early stage, thus saving the patient from the side effects as well as the risk 
of inappropriate treatment by tamoxifen. 
(92 words)  
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Abstract 
Purpose: Adjuvant tamoxifen treatment revolutionized the management of estrogen 
receptor (ER) positive breast cancers to prevent cancer recurrence; however drug 
resistance compromises its clinical efficacy. The mechanisms underlying tamoxifen 
resistance are not fully understood and no robust biomarker is available to reliably 
predict those who will be resistant. Here we study BQ323636.1, a novel splice variant 
of the NCOR2 gene and evaluate its efficacy in predicting tamoxifen resistance in 
breast cancer patients. 
Experimental Design: A monoclonal anti-BQ323636.1 antibody that specifically 
recognizes the unique epitope of this splice variant was generated for in vitro 
mechanistic studies and for in vivo analysis by immunohistochemistry on tissue 
microarrays of two independent cohorts of 358 patients with more than 10 years clinical 
follow-up data, who had ER-positive primary breast cancer and received adjuvant 
tamoxifen treatment. Orthotopic mouse model was also used.  
Results: Overexpression of BQ323636.1 conferred resistance to tamoxifen in both in 
vitro and in orthotopic mouse model. Mechanistically, co-immunoprecipitation showed 
BQ could bind to NCOR2 and inhibit the formation of co-repressor complex for the 
suppression of ER signaling. Nuclear BQ overexpression in patients samples was 
significantly associated with tamoxifen resistance (p= 1.79 x 10
-6
, sensitivity 52.9%, 
specificity 72.0%). In tamoxifen-treated patients, nuclear BQ overexpression was 
significantly correlated with cancer metastasis and disease relapse. Nuclear BQ was 
also significantly associated with poorer overall survival (p=1.13 x 10
-4
) and disease-
specific survival (p=4.02 x 10
-5
). 
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Conclusions: These findings demonstrate that BQ can be a reliable biomarker to 
predict tamoxifen resistance in ER-positive breast cancer patients. 
(249 words) 
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Introduction 
Breast cancer is the most common female malignancy. The Estrogen Receptor (ER) 
signaling pathway is a fundamental pro-proliferative pathway in the context of breast 
cancer (1). Upon its activation by binding with estrogen, ER activates target gene 
transcription and cell growth either directly through its genomic pathway or indirectly 
through non-genomic pathway that involves the PI3K/AKT pathway. Most of the well-
characterized ER-target genes are oncogenic that could promote cancer cell 
proliferation or apoptosis resistance; e.g. cyclin D1, anti-apoptotic Bcl2, and pS2  (2-4).  
Around 70% of breast cancer patients are ER positive and can benefit from anti-
estrogen therapy. Tamoxifen is a selective estrogen receptor modulator (SERM) that 
acts as an antagonist of estrogen in the context of breast and has been the most 
commonly prescribed anti-estrogen drug for preventing ER+ patients from cancer 
relapse or metastasis for over four decades (5). Binding of tamoxifen to ER triggers the 
recruitment of nuclear co-repressor 2 (NCOR2) as well as other co-repressors, such as 
GPS2, TBLR1, HDAC3, to suppress the pro-proliferative ER signaling pathway (6-8). 
In this co-repressive machinery, NCOR2 interacts with itself between regions 
encompassing amino acids 290-427 and 1788-1903 to form dimers in an anti-parallel 
fashion, serving as a central platform on which additional co-repressor proteins 
assemble (9).  The NCOR2 protein consists of four known repression domains within 
the N-terminal portion (denoted RD1 to RD4) and a series of two C-terminal nuclear 
receptor interaction domains (denoted S1 and S2) (10, 11). Alternative splicing of 
NCOR2 at the C-terminal is commonly reported, generating multiple corepressor 
isoforms with conserved repression domains but with different affinities for different 
nuclear receptors (12, 13).  
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In the adjuvant setting, a large number of patients who have ER+ tumors are treated 
with tamoxifen for prevention of disease relapse and metastasis. Despite the success of 
tamoxifen, resistance is an outstanding problem with up to 50% of non-responding 
patients with many initial responders experiencing relapse (14). However, there is no 
clinically in-use biomarker for prediction of patients’ response to tamoxifen and the 
mechanisms for developing tamoxifen resistance are still not well understood.  
By SpliceArray profiling, our group has reported a novel splice variant of NCOR2, 
named BQ323636.1 (BQ in short), with truncation at the C-terminus, retaining only the 
RD1 (15). In a cohort of 77 breast cancer patients, at the mRNA level, BQ323636.1 
overexpression was significantly associated with tamoxifen resistance, poor overall and 
disease-free survival (15). The result led us to postulate that this splice variant could 
serve as a biomarker for prediction of tamoxifen response. BQ is capable of modulating 
transcription of ER by counteracting the transcription repressive activity of NCOR2 
(15), suggesting that it could confer tamoxifen resistance and mediate cancer cell 
growth through competing and counteracting the repressive functions of its wild type.  
Our previous study only focused on association of BQ32636.1 with tamoxifen 
resistance at the mRNA level because there was no commercially antibody available to 
distinguish this isoform from its wild-type and the molecular mechanism through which 
BQ could confer resistance to tamoxifen was unknown. In the present study, we 
generated a mouse monoclonal antibody specific for BQ323636.1, confirmed the role 
of BQ323636.1 in conferring tamoxifen resistance at protein level using both in vitro 
and in vivo models and characterized the molecular mechanism through which 
BQ323636.1 confers resistance to tamoxifen. Most importantly, we also confirmed in 
two independent breast cancer cohorts from Hong Kong and the United Kingdom that 
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BQ, applied in immunohistochemical staining (IHC) on formalin fixed paraffin 
embedded primary breast cancer tissue, could be a reliable biomarker in predicting 
tamoxifen resistance.  
 
Materials and Methods 
Cell culture 
Human breast cancer cell lines MCF-7 and ZR-75-1 were purchased from American 
Type Culture Collection (ATCC) and were re-authenticated by short tandem repeat 
profiling (15). MCF-7 was cultured in Dulbecco's Modified Eagle's Medium 
supplemented with 10% FBS and 1% penicillin/streptomycin. ZR-75-1 was cultured in 
Improved Minimum Essential Medium (IMEM) supplemented with 5% FBS and 1% 
penicillin/streptomycin. LCC2 and AK-47 are two tamoxifen resistant cell lines derived 
from MCF-7 and ZR-75-1 respectively, kindly provided by Dr. Robert Clarke 
(Georgetown University Medical School, Washington, D.C.) (16) and used in our 
previous study (15). LCC2 and AK-47 were both cultured in IMEM supplemented with 
5% charcoal-stripped FBS and 1% penicillin/streptomycin. MCF-10A was purchased 
from ATCC and cultured in MEGM™ Mammary Epithelial Cell Growth Medium 
(Lonza) with 100 ng/ml cholera toxin, 0.5 mg/ml Hydrocortisone, 20 ng/ml EGF, 10 
μg/ml Insulin, 5% FBS and 1% penicillin/streptomycin. All the cell lines used in this 
study have been passaged and kept fewer than 6 months after the re-authentication or 
thawing  
 
Total RNA extraction, reverse transcription and real-time quantitative PCR 
 9 
 
TRIzol reagent (Invitrogen) was used for total RNA extraction following 
manufacturer’s protocol. Up to 2 µg total RNA were reverse transcribed into cDNA by 
SuperScript III reverse transcriptase (Invitrogen) following manufacturer’s protocol. 
Real-time PCR reaction was carried out with ABI 7900HT Fast Real-time PCR system. 
The primer sequences used were presented in Supplementary Table S1. 
 
Western blot analysis 
Cell lysates were prepared as previously described (17). The proteins were probed with 
antibody against BQ3236363.1 (Patent Cooperation Treaty filed), NCOR2 (ab24551, 
Abcam), ER (HC-20, Santa Cruz), 6xHis-tag (9F2, Wako), β-tubulin (H-235, Santa 
Cruz), lamin B (C-20, Santa Cruz) and -actin (AC-74, Sigma). Secondary antibodies 
were: HRP–conjugated anti-rabbit antibody (P0448, Dako), HRP-conjugated affiniPure 
anti-mouse antibody (Jackson Immnuno Research Laboratories),  HRP-conjugated anti-
goat antibody (SC2922, Santa Cruz). Protein A–HRP (ThermoFisher Scientific) was 
used to avoid detection of the heavy and light chains. The images were digitalized and, 
if necessary, processed by adjusting brightness or contrast only.  
 
MTT assay 
Cell viability was studied by MTT assay as previously described (15). 4-hydroxy 
tamoxifen (4-OH tamoxifen), an active metabolite of Tamoxifen was used. 4-OH 
tamoxifen and 17-β-estrodiol (E2) were purchased from Sigma and were dissolved in 
ethanol for in vitro assay. 
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Co-immunoprecipitation  
Cells were lysed in IP lysis buffer and pre-cleared with 30 µl of Dynabeads Protein 
A/G by rotating at 4
0
C for 4 hours. After pre-clearing, protein concentration was 
measured and the lysate split into equal amount of proteins per tube and incubated with 
specific primary antibody or IgG negative control at 4
0
C for O/N with gentle rotating. 
On the second day, 40μl of beads were added to the mixture and incubated at 40C for 
another 4 h. After incubation, the beads were washed 5 times with cold PBS and boiled 
at 100
0
C in 1X SDS loading dye for 5 min to elute the proteins. Proteins were separated 
by SDS–PAGE gel electrophoresis, transferred to nitrocellulose membrane and 
hybridized with the antibodies same as Western blotting. 
 
Orthotopic mouse model 
Female nude mice, aged 5 to 6 weeks were used for this study. On the day of 
inoculation, 1x10
6
 ZR-75-1 cells or 5x10
6
 MCF-7 cells were mixed with Matrigel (BD 
Bioscience) at a ratio of 1:1 and the 100µl cell mixture injected into the abdominal 
mammary fat pad of mice. When the tumors were palpable, mice were randomized into 
treatment and control groups where treatment group received 4-OH tamoxifen (Sigma) 
dissolved in ethanol and diluted in peanut oil (Sigma), given by subcutaneous injection 
500 μg per day (500 μg/ml) for 6 consecutive days per week. The control group 
received solvent only. The tumor sizes were measured regularly using calipers and the 
tumor volume calculated as longest diameter x (shortest diameter)
2
/2. At the endpoint 
of experiment, mice were euthanized and tumors were harvested. All the procedures 
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have been reviewed and approved by HKU Committee on the Use of Live Animals in 
Teaching and Research (CULATR No.:3259-14). 
 
Pulse-chase assay  
Before pulse labelling, the cells were incubated in plain DMEM without methionine 
and cysteine (DMEM –met/cys, Gibco) for one hour. While waiting, 35S-methoinine 
stock (43.3 mCi/ml, Perkin-Elmer) was diluted in DMEM –met/cys supplemented with 
10% FBS (working concentration was 0.2 mCi per 100mm culture dish (hot medium). 
After cell starvation, hot medium was added and the cells labelled with 
35
S for 1 hour. 
After the pulse period, the hot medium was removed, cells were washed and harvested 
at indicated time points (chase period). Cell pellets were collected and lysed for 
immunoprecipitation (IP) using anti-NCOR2 antibody (Abcam) or anti-BQ323636.1 
antibody (PCT filed) and the samples analyzed by SDS-PAGE.  
 
Tissue Microarray 
Two independent cohorts totaling 2095 breast cancer patients with pathological and 
clinical follow up data of over 20 years were used for this study. The cohort from Hong 
Kong comprised of 234 cases of breast cancer diagnosed between the years 1992 to 
2008 retrieved from the records of the Department of Pathology, Queen Mary Hospital 
of Hong Kong, with approval by the Institutional Review Board of The University of 
Hong Kong (UW 08-147). The remaining 1861 cases were obtained from Nottingham 
University Hospital which consisted of a large cohort of patients comprising a well-
characterized consecutive series of early stage sporadic primary operable invasive 
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breast cancers from patients enrolled into the Nottingham Tenovus Primary Breast 
Carcinoma Series that presented at Nottingham City Hospital between 1989 and 1998. 
The study was approved by the Nottingham Research Ethics Committee 2 under the 
title ‘Development of a molecular genetic classification of breast cancer’.  
All patients had early operable primary breast cancer undergoing surgery as their 
primary treatment.  TMA sections were obtained from the surgical resection samples. 
Histological sections of all cases were reviewed by the pathologist, the representative 
paraffin tumor blocks were chosen as donor block for each case and the selected areas 
were marked for construction of TMA blocks. For the Hong Kong cohort, each case 
was constructed as duplicate in the TMA and average score of the duplicate was taken 
as the score.  
There were from both cohorts, a total of 1271 cases that could be assessed and scored 
for BQ323636.1 staining. Of these 1271 primary breast cancer samples, 358 cases were 
ER positive, and had been given adjuvant tamoxifen treatment with available follow-up 
clinical data. Tamoxifen resistance is defined as patients who had been treated with 
tamoxifen in the adjuvant setting but subsequently developed disease relapse or distant 
metastases. Only cases with clear history of tamoxifen response were used for analysis. 
 
Immunohistochemistry 
The IHC was performed as previously described (17). BQ323636.1 antibody (clone D-
12) was at diluted 1:50. Aperio ScanScope ® system (Aperio technology, USA) was 
used to assess BQ323636.1 expression. The intensities and percentages of the nuclear 
staining were scored by two independent individuals using H-scoring system (18). H- 
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score = (1 × % of cells stained at intensity category 1) + (2 × % of cells stained at 
intensity category 2) + (3 × % of cells stained at intensity category 3). The cutoff was 
set as the median of H-score, which was 130. 
 
Statistical analysis 
Results were compared by two-tailed students’ t-test in Excel unless otherwise stated. 
Data from TMA were analyzed in SPSS (IBM, version 20). Where appropriate, the data 
were dichotomized into two groups including high or low expression using median 
expression level as cutoff. The correlations were analyzed by Chi-square tests. The 
expression levels of BQ were compared between different groups using Mann-Whiney 
U Rank test. Survival analyses were done by Kaplan–Meier estimates followed by Log-
rank test, and Cox regression model. P values of less than 0.05 were considered 
statistically significant. In the figures, data was expressed as mean ± sd; ‘*’ indicates p 
<0.05, ‘**’ indicates p<0.01 and ‘***’ indicates p<0.001. 
Methods for immunofluorescent staining transient transfection and luciferase assay, 
lentiviral transfection for generation of stable cell line and subcellular fractionation are 
described in supplementary material and methods.  
 
Results 
BQ323636.1 is overexpressed in tamoxifen resistant breast cancer cells 
The monoclonal anti-BQ323636.1 antibody was generated by InVivo Biotech, 
Germany, and the protocol for antibody generation and quality control is described in 
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supplementary material and methods. The epitope of this antibody maps to the last 11 
amino acid residues on BQ323636.1 protein which distinguish the variant from its 
wildtype. 
To confirm the correlation between BQ and tamoxifen resistance, we examined the 
expression level of BQ in two pairs of cell lines: MCF-7 (ER+ve, tamoxifen sensitive) 
vs LCC2 (ER+ve, tamoxifen resistant) and ZR75-1 (ER+ve, tamoxifen sensitive) vs 
AK47 (ER-ve, tamoxifen resistant). The expression level of BQ323636.1 was examined 
by western blot using our generated anti-BQ323636.1 specific antibody. Results 
showed that both mRNA and protein expression of BQ was higher in tamoxifen 
resistant cells (Figures 1A&B) compared with tamoxifen sensitive cells.  
 
BQ323636.1 overexpression induced tamoxifen resistance in vitro and in vivo 
To confirm the effect of BQ on tamoxifen resistance, BQ was stably overexpressed 
using lentiviral transduction system in tamoxifen sensitive cell lines MCF-7 and ZR-75-
1 which express low levels of BQ323636.1. Overexpression of BQ323636.1 was 
confirmed by RT-qPCR and western blot (Supplementary Figure 1). The responses of 
ZR75-1-BQ/ZR75-1-vec and MCF-7-BQ/MCF-7-vec to tamoxifen treatment were 
studied by MTT assay. Overexpression of BQ could significantly induce resistance to 
tamoxifen in both ZR-75-1 and MCF-7 cell lines (Figures 1C&D). This result was 
consistent with our previous finding using transient transfection (15) and strengthens 
the evidence supporting a role of BQ323636.1 in tamoxifen resistance.  
The involvement of BQ323636.1 in tamoxifen resistance was further confirmed using 
an in vivo mouse model. As shown in Figure 1E, ZR75-1-vec tumors were sensitive to 
tamoxifen treatment as marked by significant reduction of tumor growth when 
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compared with control. In comparison, BQ323636.1-overexpressed tumors did not 
respond to tamoxifen treatment (Figure 1F). Similar results were also observed using 
MCF-7 (Supplementary Figure 2), showing that the effects were not cell line specific. 
Taken together, these results provide solid proof to support the claim that BQ323636.1 
overexpression was one of the factors contributing to tamoxifen resistance.  
 
 
BQ323636.1 competed with NCOR2  
Having established that BQ323636.1 overexpression could confer tamoxifen resistance, 
the next step was to understand the mechanism. It has been observed that this splice 
variant could modulate transcription of ERE-containing luciferase reporter in a way 
opposite to its wildtype (15). Since NCOR2 in response to tamoxifen functions as a co-
repressor to suppress ER-target genes, therefore it was hypothesized that BQ323636.1 
could compete with NCOR2 to restrict the suppressive functions of NCOR2, which in 
turn relieved the transcriptional suppression imposed by tamoxifen.  
To test this, the effects of BQ323636.1 and/or NCOR2 overexpression on transcription 
of ERE-containing luciferase reporter (ERE-E1b-luc) were studied and the results were 
expressed as relative luciferase activity normalized against the vector control. 
Consistent to its co-repressor role in breast cancer, ectopic overexpression of NCOR2 
was found to suppress luciferase activities in both ZR-75-1 and MCF-7 in all three 
conditions including non-treated (EtOH), treated with E2 or treated with tamoxifen 
(Figures 2A&B). However, when BQ323636.1 was overexpressed together with 
NCOR2, the luciferase activities were significantly higher when compared with 
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NCOR2 overexpression alone (Figures 2A&B), indicating that the suppression on 
luciferase activity imposed by NCOR2 was, at least partially, rescued.  
It was of great importance to understand how BQ could interfere with the functions of 
NCOR2. From these and previous results (15), BQ did not appear to exert a dominant 
negative effect on NCOR2, but instead, competed with NCOR2. It has been reported 
that NCOR2 functions as a dimer in the co-repressor complex by binding to itself in an 
anti-parallel fashion (aa290-427 binds to aa1788-1903) (9), serving as a central dock 
for the further recruitment of other co-repressor proteins. As BQ protein retains only 
the RD1 portion of NCOR2, theoretically, it would have lost the ability to interact with 
ER and with other co-repressor proteins such as HDACs. Therefore, we proposed that 
BQ323636.1 could bind to NCOR2, forming a defective platform to which other co-
repressor proteins cannot be fully recruited.  
To test this conjecture, co-immunoprecipitation was first performed to study the 
interactions among ER, NCOR2 and BQ. As shown in figures 2C, the interaction 
between NCOR2 and ER was confirmed in ZR-75-1 and MCF-7. More importantly, it 
was found that BQ323636.1 interacted with NCOR2 but not with ER, consistent with 
the prediction and supporting the notion that BQ323636.1 bound to NCOR2. 
Furthermore, tamoxifen resistant cells express more BQ which compete with NCOR2, 
hence it is expected that less NCOR2 be available for interaction with ER in LCC2 
compared with tamoxifen sensitive cell MCF-7 as shown in Fig 2C(iii). 
Next, the effects of BQ323636.1 overexpression on the interactions between NCOR2 
and the co-repressor proteins HDAC3, TBLR1 and GPS2 were studied by Co-IP. To 
this end, the effects of BQ323636.1 on the expressions of NCOR2, HDAC3, TBLR1 
and GPS2 were first examined by Western blot. It was observed that BQ323636.1 
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overexpression did not alter the expression levels of these proteins (Supplementary 
Figure 3). Co-IP further revealed that BQ323636.1 overexpression suppressed the 
interaction between HDAC3 and NCOR2, GPS2 and TLBR1 respectively for the 
tamoxifen sensitive cell lines MCF-7 and ZR-75 (Figures 2D(i) & (ii)). Likewise, 
tamoxifen resistant cells LCC2 which express more BQ that competes with NCOR2, 
suppress the interaction between HDAC3 and NCOR2, GPS2 and TLBR1 respectively 
when compared with MCF-7 (Fig 2D (iii)).  
Under normal conditions, ERα binds to estrogen response element (ERE) of different 
genes such as GREB, LY6E, NRIP and pS2 to initiate the transcription (19). NCOR2 
can bind to ERα on ERE to form a gene repressor complex which can thus repress the 
effect on ERα on transcription (20). ChIP assays performed showed that overexpression 
of BQ could reduce the amount of NCOR2 interacting with the ERE genes pS2, NRIP, 
LY6E and GREB (Supplementary Figure 4). Collectively, these data suggest that 
BQ323636.1 binds to NCOR2, to functionally interfere with the formation of NCOR2 
gene co-repressor complex of ERα, thus confirming that the recruitment of the co-
repressor complex to the endogenous gene promoters is indeed affected by BQ 
overexpression. 
 
BQ323636.1 protein had a higher stability than NCOR2 protein 
It had been previously observed that whilst protein levels of BQ323636.1 were high, 
there were very low expression levels of BQ323636.1 mRNA compared with the 
NCOR2 wild-type, suggesting there may be some post-transcriptional mechanism 
regulating BQ323636.1 expression (15). The phosphorylation site Ser2410 on NCOR2 
reported to be responsible for proteasome-mediated degradation is deleted in 
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BQ323636.1. Thus, compared with NCOR2, BQ323636.1 may be less susceptible to 
degradation. To study the proteasome-mediated degradation of BQ323636.1, MCF-7 
and ZR-75-1 were treated with MG132, a potent proteasome inhibitor, for a time course 
as indicated in Figures 3A&B. It was found that MG132 treatment could cause the 
accumulation of NCOR2 but not BQ323636.1, suggesting that NCOR2 protein was 
actively degraded through the proteasome-mediated degradation pathway whilst 
BQ323636.1 was not. To gain definite knowledge of the turnover of these two proteins 
in the cells, pulse-chase analyses were performed to determine the half-life. It was 
found that NCOR2 degraded continuously along with time, while BQ323636.1 protein 
stayed relatively constant after an initial decrease from 0 h to 2 h (Figure 3C). The half-
life of NCOR2 was around 4 h while that of BQ323636.1 was undetermined using the 
same time course (Figure 3C). Overall, our finding indicated that BQ323636.1 protein 
would have a higher stability than NCOR2 protein, probably because of the impaired 
proteasome-degradation pathway.  
 
BQ323636.1 nuclear overexpression is associated with tamoxifen resistance in breast 
cancer patient samples 
Previously, in a small cohort of 77 breast cancer patients, we have shown that 
BQ323636.1 overexpression at mRNA level is significantly associated with tamoxifen 
resistance (15). As we have demonstrated, the BQ323636.1 protein binds to NCOR2 to 
suppress the formation of co-repressor complexes. Hence more informative results can 
be obtained by assessing BQ323636.1 protein expression in relation to tamoxifen 
resistance.  With the use of the specific monoclonal anti-BQ323636.1 antibody, protein 
expression of BQ323636.1 was directly examined in breast cancer tumor tissue by 
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immunohistochemistry as in vivo confirmation of the usefulness of BQ323636.1 as a 
predictive marker for tamoxifen resistance. 
Representative images of IHC staining are shown in Figure 4A. It was observed that, 
whilst BQ323636.1 was expressed in the cytoplasm at a fairly similar level for all 
patients, the intensity and distribution of nuclear BQ323636.1 staining was 
heterogeneous and varied from patient to patient.  Hence, semi-quantitative assessment 
of nuclear BQ323636.1 expression levels was performed using the H-score system 
which takes into account both the intensity and percentage of cells stained at the 
intensity category, which was named BQ nuclear score.  
Three hundred and fifty eight ER+ primary breast cancer samples recruited from two 
independent Hong Kong and United Kingdom cohorts were used for analysis. All 
patients had received adjuvant tamoxifen treatment with available follow-up clinical 
data and clear history of tamoxifen response. Tamoxifen resistance is defined as 
tamoxifen treated patients who subsequently developed disease relapse or distant 
metastases. The clinicopathological data of these 358 cases are shown in 
Supplementary Table 1, for which 78 cases were from Hong Kong and 280 cases from 
the United Kingdom. Both cohorts of patients when analyzed separately, each gave 
statistically significant results (Supplementary figures 5&6), and the pooled results are 
presented.  
Statistical analysis revealed the BQ nuclear score was significantly associated with 
tamoxifen resistance by Chi-square test (p= 1.79 x 10
-6
), and significantly higher in 
patients found to be tamoxifen resistant (Mann-Whitney U-Rank test, p=0.001, figure 
4B). In tamoxifen treated patients, BQ nuclear score was significantly correlated with 
cancer metastasis (Chi-square test, p= 4.27 x 10
-7
) and significantly higher in patients 
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who developed metastasis (Mann-Whitney U-Rank test, p=0.00009, figure 4C). BQ 
nuclear score was also significantly associated with disease relapse (Chi-square test, 
p=1.87 x 10
-4
) and significantly higher in patients who developed disease relapse 
(Mann-Whitney U Rank test, p=0.018, figure 4D).  
Consistent with its role in predicting tamoxifen resistance, BQ nuclear score was 
significantly associated with poorer survival by Kaplan-Meier estimate (Log-rank test, 
p=1.13 x 10
-4
 and p=4.02 x 10
-5
 for overall survival and disease-specific survival, 
respectively, figures 4E&F). By Cox-regression analysis (Table 1), it was also observed 
that BQ nuclear score was significantly associated with poorer overall survival 
RR=1.765, 95% CI 1.317 to 2.365; p=1.42 x 10
-4
) as well as with poorer disease-
specific survival (RR=2.093, 95% CI 1.459 to 3.002; p=6.03 x 10
-5
).  Multivariate cox-
regression analyses showed that after adjustment for age, tumor stage, tumor grade and 
progesterone receptor (PR) status, BQ nuclear score remained to be significantly 
associated with higher risk of death; overall survival (RR=2.117, 95% CI 1.520 to 
2.948; p=9.18 x 10
-6
) and for disease-specific survival (RR=2.604 , 95% CI 1.746 to 
3.885; p=2.74 x 10
-6
).  
With the use of nuclear BQ score, this scoring method could predict tamoxifen 
resistance of the breast cancer patients with a sensitivity of 52.9%, specificity of 72.0%. 
Positive predictive value is 59.0% while the negative predictive value is 66.7%. The 
results indicate that BQ323636.1 overexpression is an independent prognostic marker 
for patients who have received tamoxifen treatment, consistent with its role in 
predicting tamoxifen resistance. 
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Discussion 
The estrogen (ER) signaling pathway is an important pro-proliferative pathway in 
breast cancer, which upon binding with estrogen, activates target gene transcription and 
cell growth. More than two-thirds of breast cancer patients are ER+ and can be treated 
with endocrine therapy. Tamoxifen is most commonly prescribed to ER+ patients for 
the prevention of breast cancer relapse or metastasis, but despite significant successes 
in improving patients’ survival, tamoxifen resistance remains an outstanding issue (14). 
The binding of tamoxifen to ER triggers the recruitment of NCOR2 as well as other co-
repressors such as GPS2, TBLR1, HDAC3, to suppress the ER-mediated cell 
proliferative signaling pathway (6-8). The mechanisms underlying tamoxifen resistance 
have been extensively studying but not yet well understood.  
The pharmacological activity of tamoxifen is dependent upon its conversion by the 
metabolic enzyme CYP2D6 to its active metabolite, endoxifen. Patients with reduced 
CYP2D6 activity, were considered to benefit less from tamoxifen treatment and 
CYP2D6 became a patented marker for prediction of tamoxifen response (21, 22). 
Subsequent clinical studies however have reported conflicting results, some supportive 
that patients with reduced CYP2D6 activity derive inferior therapeutic benefit from 
tamoxifen (23), whilst others finding the contrary (24). Therefore, it remains 
questionable whether CYP2D6 can serve as a robust biomarker for predicting tamoxifen 
resistance.  
Therefore there is as yet no available robust biomarker to discriminate ER+ patients 
who will be sensitive to tamoxifen from those who will be resistant. Patients with ER+ 
disease will thus be prescribed with tamoxifen but clinicians can only document drug 
failure when cancer reoccurs and/or metastasizes. 
 22 
 
BQ323636.1 is a splice variant of NCOR2 identified by our group with exon 11 
skipping during mRNA splicing, resulting in an early translation stop codon and a 
truncated protein product retaining only the N-terminal fragment compared to its wild-
type (15). Although BQ mRNA level is 2% to 5% of NCOR2, BQ323636.1 protein, on 
the other hand, was found to be expressed at similar levels to NCOR2 (15). This could 
be due in part to BQ323636.1 being not actively degraded through the proteasome-
mediated pathway with a longer half-life in the cell compared with that of NCOR2, or 
that the translation efficiency of BQ323636.1 was higher than NCOR2. These 
mechanisms could help maintain protein expression of BQ323636.1 at a functionally 
significant level in the cell. The fact that NCOR2 functions as a dimer and that 
BQ323636.1 binds to NCOR2 could amplify the functional importance of the splice 
variant in the cells.  
In this study, in vitro and in vivo evidence was presented to support that BQ323636.1 
overexpression could confer tamoxifen resistance. Moreover, the functional roles of 
BQ323636.1 were studied. BQ323636.1 overexpression rescued the suppressive effect 
of NCOR2 overexpression exerted on the transcription of an ERE-containing luciferase 
reporter and compromised the inhibitory effects of tamoxifen on ER-target gene 
expression. Such effects can be explained by the fact that BQ323636.1 binds to NCOR2 
but not to ER in the cells and that BQ323636.1 overexpression inhibits the interaction 
between HDAC3 and NCOR2, GPS2 and TBLR1 respectively, indicating the 
suppressed formation of co-repressor complex. Based on our findings, the mechanism 
by which BQ323636.1 overexpression contributes to tamoxifen resistance is proposed 
as follows (figure 6). In the absence of BQ323636.1, in response to tamoxifen treatment, 
NCOR2 homo-dimerizes in an anti-parallel fashion, serving as a dock for further 
recruitment of other co-repressor proteins, such as TBLR1, HDACs and GPS2, to form 
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a complete and functional co-repressor complex which will bind to ER to suppress gene 
transcription and halt cell growth. In contrast, when BQ323636.1 is present, it binds to 
NCOR2, forming a faulty dock to which other co-repressor proteins cannot be fully 
recruited, resulting in a defective co-repressor complex which cannot bind to ER or is 
unable to fully suppress gene transcription (Figure 6). Hence the cells become inert to 
tamoxifen treatment.  
Statistical analyses using TMA constructed from 358 primary breast cancer samples 
obtained from two independent cohorts of patients, recruited from Hong Kong and from 
the United Kingdom showed that, for patients who have been treated with tamoxifen, 
BQ323636.1 nuclear overexpression is significantly associated with tamoxifen 
resistance (Chi square test, p<0.001), which is defined as disease relapse or metastasis 
after being treated with tamoxifen. The correlation between nuclear BQ323636.1 
enrichment and tamoxifen resistance is also observed in cell lines. It is also noted that, 
not only BQ323636.1 is expressed at higher levels in tamoxifen resistant cell lines 
(LCC2 and AK47) when compared with their parental tamoxifen sensitive cell lines 
(MCF-7 and ZR-75), but nuclear localization is observed more distinctly in tamoxifen 
resistant cell lines LCC2 and AK-47. Based on the existing knowledge, when present in 
the nucleus, BQ323636.1 is likely to be functionally active to mediate tamoxifen 
resistance. It is not yet clear why BQ323636.1 is expressed in both the cytoplasm and 
nucleus. Moreover, would be very interesting to further study what regulates the 
shuttling of BQ323636.1 between nucleus and cytoplasm.  
Nuclear BQ323636.1 overexpression was significantly associated with tamoxifen 
resistance by Chi-square test, p= 1.79 x 10
-6
 with a sensitivity of 52.9% and specificity 
of 72.0%. The performance of BQ as a biomarker of tamoxifen response can be further 
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improved using an expanded cohort. On the other hand, the cytoplasmic staining of BQ 
in IHC may have interfered with scorer’s interpretation of nuclear BQ expression. 
Unlike NCOR2, which is localized only in the nucleus, BQ was found to be expressed 
in both cytoplasm and nucleus. This raises a very interesting question as to what are the 
differences between cytoplasmic and nuclear BQ and what mechanisms, such as post-
translational modifications, controls the shuttling of this protein between the cytoplasm 
and the nucleus. By investigating such questions, it may be possible to generate an 
antibody that specifically recognizes nuclear BQ, thus improving the accuracy of 
tamoxifen response prediction. Phosphorylation is a key regulatory step redirecting 
cellular localization between the cytoplasm and nucleus of many proteins. For example, 
nuclear iASSP, which is enriched in melanoma metastasis and associated with poor 
patient survival, is the phosphorylated form of iASSP and phosphorylation by cyclin 
B1/CDK1 on Ser-84 and Ser-113 triggers iASSP to enter the nucleus (25). 
Phosphorylation of FOXO3 on Ser-7 by p38 MAPK triggers the transition of FOXO3 
from cytoplasm to nucleus upon doxorubicin treatment (26). Therfore, it is postulated 
that phosphorylation profile may distinguish nuclear from cytoplasmic BQ, and 
phosphorylation could signal BQ to enter the nucleus from the cytoplasm.  
Aromatase inhibitors (AI) act by inhibiting the synthesis of estrogen from androgen by 
blocking the activity of the aromatase CYP19A1, resulting in reduced estrogen for 
induction of the ER-mediated signaling pathway (27). Our studies have confirmed that 
BQ activates ER-mediated signaling pathway in a ligand independent manner. 
Overexpression of BQ significantly enhanced the activity of ERE even in the absence 
of estrogen or tamoxifen (Figures 2 A&B), therefore it is likely that BQ may also be a 
predictive marker for AI resistance. This needs confirmation with a cohort of patients 
with available information of AI treatment and response. 
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To conclude, the current study has provided in vitro and in vivo evidence to support the 
notion that BQ overexpression could confer tamoxifen resistance and that BQ could be 
used as a predictive marker for patients’ response to tamoxifen treatment. The 
molecular mechanism through which BQ could induce tamoxifen resistance has also 
been studied and proposed. More studies are required using patient samples from 
different ethnic backgrounds to further verify the reliability of BQ in predicting 
tamoxifen resistance. Furthermore, it would be interesting to investigate the 
significance of BQ overexpression in relation to treatment with other novel anti-
estrogens. 
(4,990 words) 
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Figure legends 
Figure 1. BQ323636.1 is overexpressed in tamoxifen resistant breast cancer cells 
A) mRNA expression of BQ323636.1 in different breast cell lines. qPCR was performed to 
determine the expression level of BQ in normal breast cell line (MCF-10A), Tamoxifen sensitive 
breast cancer cell lines (MCF-7 and ZR-75) and Tamoxifen resistant cell lines (LCC2 and AK-
47). Actin was used as internal control. B) Protein expression of BQ323636.1 in Tamoxifen 
sensitive and resistant cell lines. Western blot was performed to determine the protein level of 
BQ323636.1. Actin was used as a loading control.  
Overexpression of BQ323636.1 conferred Tamoxifen resistance in vitro and in vivo 
Overexpression of BQ323636.1 induced Tamoxifen resistance in the sensitive cell lines C) 
MCF-7 and D) ZR-75. The cells were treated with different concentration of Tamoxifen for 72 
hours. MTT assay was performed to determine the cell viability. Samples were triplicated. E) 
Treatment of Tamoxifen could reduce xenograft tumor volume in control ZR-75 cells and as 
illustrated in the growth curve. The number of mice used in control group and treatment group 
were 4 and 4 respectively F) Overexpression of BQ323636.1 induced Tamoxifen resistance in 
vivo and as illustrated in the growth curve. The number of mice used in control group and 
treatment group were 4 and 5 respectively. % of tumor volume change was presented as mean ± 
s.d. Data was expressed as mean ± s.d from three independent experiments. * represents p<0.05; 
** represents p<0.01; *** represent p<0.001. Statistical significance was determined by student 
T-Test.  
Figure 2. Overexpression of BQ323636.1 could rescue gene repressive function of NCOR2. 
Luciferase reporter assay was performed on A) MCF-7 and B) ZR-75 cells were treated with 
either EtOH or 0.1 nM of E2. Cells were harvested after 48 hours of the treatment. E1b-ERE 
luciferase reporter was employed. Samples were prepared in triplicate. Renilla was used as 
internal control. Data was expressed as mean ± s.d from three independent experiments. *** 
represent p<0.001. Statistical significance was determined by student T-Test.  
BQ323636.1 bound to NCOR2 and suppresses formation of co-repressor complex.  
C) Co-IP demonstrated interaction between BQ323636.1 and NCOR2 in i) MCF-7 and ii) ZR-75 
cells. iii) The interaction between ER and NCOR2 was compromised in tamoxifen resistant cells 
LCC2 compared with tamoxifen sensitive cells MCF-7. D) Overexpression BQ323636.1 
suppressed the interaction between HDAC3 and NCOR2, GPS and TBLR1 in i) MCF-7 and ii) 
ZR-75 cells. The interaction of HDAC3 with NCOR2, GPS2 and TBLR1 was compromised in 
LCC2 compared with MCF-7 cells.  
Figure 3. BQ323636.1 protein was more stable than NCOR2. BQ323636.1 protein did not 
accumulate following MG132 treatment but NCOR2 did in A) MCF-7 and B) ZR-75 cells. 5µM 
of MG132 was employed. (C) BQ323636.1 degraded slower than NCOR2 and had a longer half-
life in the cell. Band intensities were quantified by ImageJ and normalized against intensities of 
0h. Data was expressed as mean ± s.d from three independent experiments. *, p<0.05. Statistical 
significance was determined by student T-Test.  
Figure 4. The clinical significance of nuclear expression level of BQ323636.1. A) 
Representative images of BQ323636.1 IHC staining in primary breast cancer samples in TMA. 
Mann-Whitney test demonstrating BQ323636.1 nuclear score was associated with B) Tamoxifen 
resistance C) Metastasis and D) Recurrence *** p<0.001, ** p<0.01, * p<0.05. Nuclear 
BQ323636.1 scores were dichotomized at the median value and Chi square test performed for 
association with B) Tamoxifen resistance, C) Metastasis and D) Recurrence (Chi square test 
p<0.0001). 
Kaplan-Meier estimate shows the patients with high nuclear BQ323636.1 expression were 
associated with poorer E) overall survival outcome (p < 0.001) and F) disease specific survival 
outcome (p<0.001) (Log-rank test). Nuclear BQ323636.1 scores were dichotomized at the 
median value. 
Figure 5. The proposed mechanism of how BQ323636.1 could induce tamoxifen resistance 
in breast cancer. When BQ323636.1 interacts with NCOR2, this prevents other co-repressor 
proteins such as TBLR1 and HDAC3 from binding to NCOR2, which renders NCOR2 unable to 
form functional repressor complexes to suppress ER-mediated gene transcription.  
Table 1. Survival analysis for tamoxifen-treated patients using Cox regression model. 
Variables used in the Cox regression model were dichotomized as shown in Supplementary 
Table 1. A) Higher BQ nuclear score was significantly associated with higher risk of death even 
after adjustment for clinical parameters including age, tumor grade, PR and HER2 status. 
(RR=2.117; p <0.001. B) Higher BQ nuclear score was significantly associated with higher risk 
of dying from cancer even after adjustment for clinical parameters including tumor grade, PR 
and HER2 status. (RR=2.604; p<0.001). #Cut off = 130 which is the median BQ nuclear score. 
 






